HBV Treatment
Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 12 April 2011 03:38
- Written by Liz Highleyman
Gilead's GS-9620, an experimental TLR7 agonist, stimulated interferon production and activated B-cells and T-cells in laboratory and human studies, and was active against hepatitis B and a related virus in monkeys and woodchucks, researchers reported at EASL 2011.
Telbivudine Label Adds Resistance Warning
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 05 April 2011 07:01
- Written by Press Release
Package labeling for the hepatitis B drug telbivudine (Tyzeka) was recently changed to add information about the risk of drug resistance and a recommendation for monitoring after 6 months of treatment.
Entecavir Approved in Europe for Hepatitis B Patients with Decompensated Liver Diseases
- Details
- Category: Approved HBV Drugs
- Published on Friday, 11 March 2011 09:08
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb announced early this month that the European Commission -- the regulatory authority for the European Union -- approved entecavir (Baraclude) for the treatment of hepatitis B virus (HBV) infection in patients with decompensated liver disease. The U.S. Food and Drug administration (FDA) granted similar approval this past October.
Entecavir Beats Adefovir for Hepatitis B Treatment
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 29 March 2011 10:03
- Written by Liz Highleyman
A meta-analysis of 6 studies found that entecavir (Baraclude) was more effective than adefovir (Hepsera) for treatment-naive HBeAg positive Asian chronic hepatitis B patients. 
No Tenofovir Resistance after 3 Years among Chronic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Friday, 07 January 2011 03:17
- Written by Liz Highleyman
Tenofovir (Viread) remains active against hepatitis B virus (HBV) and is not prone to drug-resistance mutations even after 3 years of treatment, according to study results published in the December 22, 2010 advance online edition of Hepatology. Further data presented at a recent liver disease conference indicate that this still remains the case after 4 years.
More Articles...
- Antiviral Therapy for Chronic Hepatitis B Patients with Decompensated Liver Cirrhosis
- Bristol-Myers Squibb Enhances Co-pay Assistance Program for Entecavir (Baraclude) for Hepatitis B
- Are IL28B Gene Variations Associated with Outcomes in People with Hepatitis B?
- Add-on Adefovir Is More Effective and Durable Than Switch to Entecavir as Rescue Therapy
Web Design and Development by